首页 > 最新文献

RSC medicinal chemistry最新文献

英文 中文
Targeting host integrated stress response: lead discovery of flavonoid compounds active against coronaviruses PEDV and PDCoV. 靶向宿主综合应激反应:率先发现抗冠状病毒PEDV和PDCoV活性类黄酮化合物。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-23 DOI: 10.1039/d4md00846d
Liang Yi, Yishuai Wang, Jiehuang Wang, Yihan Chen, Weixue Huang, Ying Liao, Qingwen Zhang

Viral infections trigger the integrated stress response (ISR) in eukaryotic cells that leads to the activation of eIF2α kinases, the elevation of eukaryotic translation initiation factor 2α (eIF2α) phosphorylation, and thereby the shutdown of global protein synthesis that viruses rely on to replicate. Coronaviruses and other viruses have evolved various subversion mechanisms to counteract the antiviral ISR. These intricate host-virus interactions may be exploited by pharmacologically activating the host ISR for the development of host-directed antivirals (HDAs), an increasingly relevant area of research. In this study, we have discovered a new class of flavonoid-based ISR activators that exhibit potent antiviral activity against porcine epidemic diarrhea virus (PEDV) and porcine deltacoronavirus (PDCoV). PEDV and PDCoV are animal coronaviruses of great veterinary and economic importance, for which there are currently no effective therapeutics. The mechanistic study indicated that lead compounds 1-B and 1-C inhibit PEDV and PDCoV replication via upregulating eIF2α phosphorylation and thereby downregulating global protein synthesis in host cells, suggesting they are HDA antivirals.

病毒感染触发真核细胞的综合应激反应(ISR),导致eIF2α激酶激活,真核翻译起始因子2α (eIF2α)磷酸化升高,从而关闭病毒复制所依赖的全局蛋白质合成。冠状病毒和其他病毒已经进化出各种颠覆机制来对抗抗病毒的ISR。这些复杂的宿主-病毒相互作用可以通过药理学激活宿主ISR来开发宿主定向抗病毒药物(HDAs),这是一个日益相关的研究领域。在这项研究中,我们发现了一类新的基于黄酮类化合物的ISR激活剂,它们对猪流行性腹泻病毒(PEDV)和猪冠状病毒(PDCoV)具有强抗病毒活性。PEDV和PDCoV是具有重大兽医和经济意义的动物冠状病毒,目前尚无有效的治疗方法。机制研究表明,先导化合物1-B和1-C通过上调eIF2α磷酸化,从而下调宿主细胞中全局蛋白的合成,从而抑制PEDV和PDCoV的复制,提示它们是HDA抗病毒药物。
{"title":"Targeting host integrated stress response: lead discovery of flavonoid compounds active against coronaviruses PEDV and PDCoV.","authors":"Liang Yi, Yishuai Wang, Jiehuang Wang, Yihan Chen, Weixue Huang, Ying Liao, Qingwen Zhang","doi":"10.1039/d4md00846d","DOIUrl":"10.1039/d4md00846d","url":null,"abstract":"<p><p>Viral infections trigger the integrated stress response (ISR) in eukaryotic cells that leads to the activation of eIF2α kinases, the elevation of eukaryotic translation initiation factor 2α (eIF2α) phosphorylation, and thereby the shutdown of global protein synthesis that viruses rely on to replicate. Coronaviruses and other viruses have evolved various subversion mechanisms to counteract the antiviral ISR. These intricate host-virus interactions may be exploited by pharmacologically activating the host ISR for the development of host-directed antivirals (HDAs), an increasingly relevant area of research. In this study, we have discovered a new class of flavonoid-based ISR activators that exhibit potent antiviral activity against porcine epidemic diarrhea virus (PEDV) and porcine deltacoronavirus (PDCoV). PEDV and PDCoV are animal coronaviruses of great veterinary and economic importance, for which there are currently no effective therapeutics. The mechanistic study indicated that lead compounds 1-B and 1-C inhibit PEDV and PDCoV replication <i>via</i> upregulating eIF2α phosphorylation and thereby downregulating global protein synthesis in host cells, suggesting they are HDA antivirals.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and synthesis of cyclic lipidated peptides derived from the C-terminus of Cx43 for hemichannel inhibition and cardiac endothelium targeting. 从Cx43的c端衍生的用于半通道抑制和心脏内皮靶向的环状脂化肽的设计和合成。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-21 DOI: 10.1039/d4md00850b
Debora Iaculli, Jade Montgomery, Arthur Lamouroux, Anne Caufriez, Rafael Gozalbes, Mathieu Vinken, Filippo Molica, Brenda R Kwak, Steven Ballet

A peptide segment that is 10 residues long at the C-terminal (CT) region of Cx43 is known to be involved in interactions, both with the Cx43 protein itself and with other proteins, that result in hemichannel (HC) activity regulation. Previously reported mimetic peptides based on this region (e.g., αCT1, CT10) have been revealed to be promising therapeutic agents in the context of cardiovascular diseases. In this work, novel approaches, such as C- and N-terminal modification and cyclization, to improve the proteolytic stability and bioavailability of the CT10 peptide are presented. These efforts resulted in a set of unprecedented potent cyclic inhibitors of HC-mediated ATP release with a half-life largely exceeding 24 hours. Additionally, the introduction of a lipophilic moiety with different solubilizing linkers led to the generation of a novel series of water-soluble and lipidated peptides that exhibited high inhibitory capacity in in vitro assays at submicromolar concentrations. A cardiac endothelium targeting strategy was also adopted, exploiting the ability of the CRPPR peptide to selectively deliver the peptides to endothelial cells.

在Cx43的c端(CT)区域有一个长达10个残基的肽段,已知与Cx43蛋白本身和其他蛋白相互作用,导致半通道(HC)活性调节。先前报道的基于该区域的模拟肽(例如αCT1, CT10)已被发现是心血管疾病中有希望的治疗药物。在这项工作中,提出了新的方法,如C端和n端修饰和环化,以提高CT10肽的蛋白水解稳定性和生物利用度。这些努力产生了一组前所未有的有效的hc介导的ATP释放环抑制剂,其半衰期大大超过24小时。此外,引入具有不同增溶连接体的亲脂性片段导致产生一系列新的水溶性和脂化肽,这些肽在亚微摩尔浓度的体外实验中表现出高抑制能力。还采用了心脏内皮靶向策略,利用CRPPR肽选择性地将肽递送到内皮细胞的能力。
{"title":"Design and synthesis of cyclic lipidated peptides derived from the C-terminus of Cx43 for hemichannel inhibition and cardiac endothelium targeting.","authors":"Debora Iaculli, Jade Montgomery, Arthur Lamouroux, Anne Caufriez, Rafael Gozalbes, Mathieu Vinken, Filippo Molica, Brenda R Kwak, Steven Ballet","doi":"10.1039/d4md00850b","DOIUrl":"10.1039/d4md00850b","url":null,"abstract":"<p><p>A peptide segment that is 10 residues long at the C-terminal (CT) region of Cx43 is known to be involved in interactions, both with the Cx43 protein itself and with other proteins, that result in hemichannel (HC) activity regulation. Previously reported mimetic peptides based on this region (<i>e.g.</i>, <b>αCT1</b>, <b>CT10</b>) have been revealed to be promising therapeutic agents in the context of cardiovascular diseases. In this work, novel approaches, such as C- and N-terminal modification and cyclization, to improve the proteolytic stability and bioavailability of the <b>CT10</b> peptide are presented. These efforts resulted in a set of unprecedented potent cyclic inhibitors of HC-mediated ATP release with a half-life largely exceeding 24 hours. Additionally, the introduction of a lipophilic moiety with different solubilizing linkers led to the generation of a novel series of water-soluble and lipidated peptides that exhibited high inhibitory capacity in <i>in vitro</i> assays at submicromolar concentrations. A cardiac endothelium targeting strategy was also adopted, exploiting the ability of the CRPPR peptide to selectively deliver the peptides to endothelial cells.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual EGFR and telomerase inhibitory potential of new triazole tethered Schiff bases endowed with apoptosis: design, synthesis, and biological assessments. 新的三唑系席夫碱具有细胞凋亡的双重EGFR和端粒酶抑制潜力:设计、合成和生物学评估。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-19 DOI: 10.1039/d4md00750f
Mohamed A Zeidan, Heba F Ashour, Asmaa S A Yassen, Ayman Abo Elmaaty, Ayman B Farag, Marwa Sharaky, Abdullah Yahya Abdullah Alzahrani, Mohammed H Al Mughram, Ahmed A Al-Karmalawy

Many cancers have displayed resistance to chemotherapeutic drugs over the past few decades. EGFR has emerged as a leading target for cancer therapy via inhibiting tumor angiogenesis. Besides, studies strongly suggest that blocking telomerase activity could be an effective way to control the growth of certain cancer cells. Based on the fact that multi-target design rationale can afford candidates with greater treatment effectiveness. Besides, it was evidenced that inhibition of human telomerase enhances the effect of some tyrosine kinase inhibitors. So, in the current work, we aimed to design and synthesize novel 1,2,3-triazole-tethered Schiff bases (5a-l) to act as dual EGFR and telomerase inhibitors. Growth inhibition (GI)% was conducted for the synthesized compounds using a panel of eleven cancer cell lines as well as two normal cell lines. Interestingly, compound 5e displayed the highest mean GI% (76.78%) among the investigated compounds surpassing the mean GI% of the reference drug doxorubicin (65.79%). In addition, compound 5g displayed notably the lowest IC50 values (13.31, 13.31, 12.62, and 31.19 μM) for the four utilized cancer cell lines HNO97, HCT116, A375, and HEPG2, respectively. Interestingly, the investigated compounds exhibited significant inhibitory potential to EGFR and telomerase protein expression; in particular, compound 5g recorded inhibitory potentials of 3.45 and 1.31 ng mL-1, respectively. Hence, protein expression of the apoptosis-related proteins was carried out for compound 5g. Pro-apoptotic proteins (caspases 3, 8, and 9) were upregulated by 1.35, 1.55, and 1.51-fold change, respectively. Meanwhile, the anti-apoptotic proteins (CDK-2, CDK-4, and CDK-6) were downregulated by 2.91, 2.01, and 9.15-fold change, respectively, ensuring the apoptotic potential of compound 5g. Accordingly, compound 5g was selected for further investigation of its effects on cell cycle progression in A375 cancer cells. Obviously, compound 5g prompted cell cycle arrest at the G0-G1 phase. Additionally, the investigated compounds showed eligible pharmacokinetic profiles with feasible oral bioavailability. Consequently, the synthesized compounds can be treated as lead multi-target anticancer ligands for future optimization.

在过去的几十年里,许多癌症都表现出对化疗药物的耐药性。通过抑制肿瘤血管生成,EGFR已成为癌症治疗的主要靶点。此外,研究强烈表明,阻断端粒酶活性可能是控制某些癌细胞生长的有效方法。基于多靶点设计原理,可以为候选药物提供更大的治疗效果。此外,有证据表明,抑制人类端粒酶可增强某些酪氨酸激酶抑制剂的作用。因此,在目前的工作中,我们旨在设计和合成新的1,2,3-三唑系结希夫碱(5a-l),作为EGFR和端粒酶的双重抑制剂。用11个癌细胞系和2个正常细胞系对合成的化合物进行了生长抑制(GI)%。有趣的是,化合物5e的平均GI%最高(76.78%),超过参比药阿霉素的平均GI%(65.79%)。此外,化合物5g对HNO97、HCT116、A375和HEPG2的IC50值最低,分别为13.31、13.31、12.62和31.19 μM。有趣的是,所研究的化合物对EGFR和端粒酶蛋白表达表现出显著的抑制潜力;其中,化合物5g的抑制电位分别为3.45和1.31 ng mL-1。因此,我们对化合物5g进行了凋亡相关蛋白的蛋白表达。促凋亡蛋白(caspases 3、8和9)分别上调1.35倍、1.55倍和1.51倍。同时,抗凋亡蛋白CDK-2、CDK-4和CDK-6分别下调2.91倍、2.01倍和9.15倍,保证了化合物5g的凋亡潜能。因此,选择化合物5g进一步研究其对A375癌细胞细胞周期进程的影响。显然,化合物5g使细胞周期阻滞在G0-G1期。此外,所研究的化合物具有合适的药代动力学特征和可行的口服生物利用度。因此,合成的化合物可以作为未来优化的先导多靶点抗癌配体。
{"title":"Dual EGFR and telomerase inhibitory potential of new triazole tethered Schiff bases endowed with apoptosis: design, synthesis, and biological assessments.","authors":"Mohamed A Zeidan, Heba F Ashour, Asmaa S A Yassen, Ayman Abo Elmaaty, Ayman B Farag, Marwa Sharaky, Abdullah Yahya Abdullah Alzahrani, Mohammed H Al Mughram, Ahmed A Al-Karmalawy","doi":"10.1039/d4md00750f","DOIUrl":"10.1039/d4md00750f","url":null,"abstract":"<p><p>Many cancers have displayed resistance to chemotherapeutic drugs over the past few decades. EGFR has emerged as a leading target for cancer therapy <i>via</i> inhibiting tumor angiogenesis. Besides, studies strongly suggest that blocking telomerase activity could be an effective way to control the growth of certain cancer cells. Based on the fact that multi-target design rationale can afford candidates with greater treatment effectiveness. Besides, it was evidenced that inhibition of human telomerase enhances the effect of some tyrosine kinase inhibitors. So, in the current work, we aimed to design and synthesize novel 1,2,3-triazole-tethered Schiff bases (5a-l) to act as dual EGFR and telomerase inhibitors. Growth inhibition (GI)% was conducted for the synthesized compounds using a panel of eleven cancer cell lines as well as two normal cell lines. Interestingly, compound 5e displayed the highest mean GI% (76.78%) among the investigated compounds surpassing the mean GI% of the reference drug doxorubicin (65.79%). In addition, compound 5g displayed notably the lowest IC<sub>50</sub> values (13.31, 13.31, 12.62, and 31.19 μM) for the four utilized cancer cell lines HNO97, HCT116, A375, and HEPG2, respectively. Interestingly, the investigated compounds exhibited significant inhibitory potential to EGFR and telomerase protein expression; in particular, compound 5g recorded inhibitory potentials of 3.45 and 1.31 ng mL<sup>-1</sup>, respectively. Hence, protein expression of the apoptosis-related proteins was carried out for compound 5g. Pro-apoptotic proteins (caspases 3, 8, and 9) were upregulated by 1.35, 1.55, and 1.51-fold change, respectively. Meanwhile, the anti-apoptotic proteins (CDK-2, CDK-4, and CDK-6) were downregulated by 2.91, 2.01, and 9.15-fold change, respectively, ensuring the apoptotic potential of compound 5g. Accordingly, compound 5g was selected for further investigation of its effects on cell cycle progression in A375 cancer cells. Obviously, compound 5g prompted cell cycle arrest at the G0-G1 phase. Additionally, the investigated compounds showed eligible pharmacokinetic profiles with feasible oral bioavailability. Consequently, the synthesized compounds can be treated as lead multi-target anticancer ligands for future optimization.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2-(4-Bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines: design, synthesis, anticancer assessment via dual topoisomerase-I/II inhibition, and in silico studies. 2-(4-溴苄基)系链4-氨基芳基/烷基-5,6,7,8-四氢苯并[4,5]噻吩[2,3-d]嘧啶:设计、合成、通过双拓扑异构酶i /II抑制的抗癌评价和硅研究。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-17 DOI: 10.1039/d4md00817k
Sahil Arora, Bhagyshree Patra, Isha Dhamija, Santosh Kumar Guru, Raj Kumar

A series of 2-(4-bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines (7a-7u) were designed, synthesized, characterized and screened against a panel of cancer cell lines. Compound 7a, in particular, emerged as a potent antiproliferative agent against FaDu cells (HTB-43) with an IC50 value of 1.73 μM. 7a induced morphological alterations in FaDu cells were observed via brightfield microscopy and DAPI staining, confirming cytotoxicity. Autophagy and apoptotic effects of 7a were confirmed by acridine orange staining, Rhodamine 123 staining, and western blot analysis, which revealed dose-dependent increases in LC3A/B and cleaved caspase-3 levels, respectively. Further, 7a impaired cell migration and colony formation, as demonstrated by scratch and clonogenic assays. Additionally, 7a reduced oxidative stress and induced G2/M phase cell cycle arrest in MCF-7 cells. 7a emerged as a dual topoisomerase I and II inhibitor, and results were supported by molecular docking and simulation studies. In anti-inflammatory studies, 7a exhibited selective inhibition of COX-2 over COX-1, supporting its dual anticancer and anti-inflammatory properties.

设计、合成了一系列2-(4-溴苄基)系链4-氨基芳基/烷基-5,6,7,8-四氢苯并[4,5]噻吩[2,3-d]嘧啶(7a-7u),并对其进行了表征和抗癌筛选。其中化合物7a对FaDu细胞(HTB-43)具有较强的抗增殖活性,IC50值为1.73 μM。通过明场显微镜和DAPI染色观察7a诱导的FaDu细胞形态学改变,证实细胞毒性。通过吖啶橙染色、罗丹明123染色和western blot分析证实7a的自噬和凋亡作用,结果显示LC3A/B和cleaved caspase-3水平分别呈剂量依赖性升高。此外,7a损伤细胞迁移和集落形成,正如划痕和克隆实验所证明的那样。此外,7a还能降低MCF-7细胞的氧化应激,诱导G2/M期细胞周期阻滞。7a作为拓扑异构酶I和拓扑异构酶II的双重抑制剂出现,这一结果得到了分子对接和模拟研究的支持。在抗炎研究中,7a表现出选择性抑制COX-2而不是COX-1,支持其抗癌和抗炎的双重特性。
{"title":"2-(4-Bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidines: design, synthesis, anticancer assessment <i>via</i> dual topoisomerase-I/II inhibition, and <i>in silico</i> studies.","authors":"Sahil Arora, Bhagyshree Patra, Isha Dhamija, Santosh Kumar Guru, Raj Kumar","doi":"10.1039/d4md00817k","DOIUrl":"10.1039/d4md00817k","url":null,"abstract":"<p><p>A series of 2-(4-bromobenzyl) tethered 4-amino aryl/alkyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidines (7a-7u) were designed, synthesized, characterized and screened against a panel of cancer cell lines. Compound 7a, in particular, emerged as a potent antiproliferative agent against FaDu cells (HTB-43) with an IC<sub>50</sub> value of 1.73 μM. 7a induced morphological alterations in FaDu cells were observed <i>via</i> brightfield microscopy and DAPI staining, confirming cytotoxicity. Autophagy and apoptotic effects of 7a were confirmed by acridine orange staining, Rhodamine 123 staining, and western blot analysis, which revealed dose-dependent increases in LC3A/B and cleaved caspase-3 levels, respectively. Further, 7a impaired cell migration and colony formation, as demonstrated by scratch and clonogenic assays. Additionally, 7a reduced oxidative stress and induced G2/M phase cell cycle arrest in MCF-7 cells. 7a emerged as a dual topoisomerase I and II inhibitor, and results were supported by molecular docking and simulation studies. In anti-inflammatory studies, 7a exhibited selective inhibition of COX-2 over COX-1, supporting its dual anticancer and anti-inflammatory properties.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinctive roles of aquaporins and novel therapeutic opportunities against cancer. 水通道蛋白的独特作用和抗癌的新治疗机会。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-17 DOI: 10.1039/d4md00786g
Dharmendra Kumar Yadav, Desh Deepak Singh, Dongyun Shin

Aquaporins (AQPs) are integral membrane proteins responsible for facilitating the transmembrane transport of water and small solutes. Their involvement in diverse physiological functions extends to pathological conditions, including cancer, positioning them as promising targets for anticancer therapy. Tumor cells, particularly those with high metastatic potential, exhibit elevated AQP expression, reinforcing their critical role in tumor biology. Emerging evidence highlights AQPs' involvement in key oncogenic processes such as cell migration, proliferation, and tumor-associated edema, suggesting their potential as novel therapeutic targets. Despite this, the development of selective and potent AQP inhibitors has proven challenging. Efforts to produce small-molecule AQP inhibitors have largely been unsuccessful. However, recent advancements include monoclonal human IgG antibodies targeting extracellular domains of aquaporin-4, offering new therapeutic strategies, particularly in glioblastoma, where AQP-4 is overexpressed. However, recent advancements include monoclonal human IgG antibodies targeting extracellular domains of aquaporin-4, offering new therapeutic strategies, particularly in glioblastoma, where AQP-4 is over expressed. These antibodies hold promise for selectively targeting and eradicating AQP-4-expressing cells in malignant brain tumors. This review discusses the critical role AQPs play in cancer, including their contributions to tumor cell proliferation, migration, angiogenesis, and edema formation. Additionally, we explore innovative therapeutic approaches, such as antibody-based interventions, and outline potential future research directions in AQP-targeted cancer therapies.

水通道蛋白(AQPs)是一种完整的膜蛋白,负责促进水和小溶质的跨膜运输。它们参与多种生理功能延伸到病理条件,包括癌症,使它们成为抗癌治疗的有希望的靶点。肿瘤细胞,特别是具有高转移潜力的肿瘤细胞,表现出AQP表达升高,加强了其在肿瘤生物学中的关键作用。新出现的证据表明AQPs参与关键的致癌过程,如细胞迁移、增殖和肿瘤相关水肿,这表明它们有潜力成为新的治疗靶点。尽管如此,选择性和有效的AQP抑制剂的开发已被证明具有挑战性。生产小分子AQP抑制剂的努力基本上是不成功的。然而,最近的进展包括针对水通道蛋白-4细胞外结构域的单克隆人IgG抗体,提供了新的治疗策略,特别是在AQP-4过表达的胶质母细胞瘤中。然而,最近的进展包括针对水通道蛋白-4细胞外结构域的单克隆人IgG抗体,提供了新的治疗策略,特别是在AQP-4过表达的胶质母细胞瘤中。这些抗体有望选择性地靶向和根除恶性脑肿瘤中表达aqp -4的细胞。本文综述了AQPs在癌症中的关键作用,包括它们对肿瘤细胞增殖、迁移、血管生成和水肿形成的贡献。此外,我们探索了创新的治疗方法,如基于抗体的干预,并概述了aqp靶向癌症治疗的潜在未来研究方向。
{"title":"Distinctive roles of aquaporins and novel therapeutic opportunities against cancer.","authors":"Dharmendra Kumar Yadav, Desh Deepak Singh, Dongyun Shin","doi":"10.1039/d4md00786g","DOIUrl":"10.1039/d4md00786g","url":null,"abstract":"<p><p>Aquaporins (AQPs) are integral membrane proteins responsible for facilitating the transmembrane transport of water and small solutes. Their involvement in diverse physiological functions extends to pathological conditions, including cancer, positioning them as promising targets for anticancer therapy. Tumor cells, particularly those with high metastatic potential, exhibit elevated AQP expression, reinforcing their critical role in tumor biology. Emerging evidence highlights AQPs' involvement in key oncogenic processes such as cell migration, proliferation, and tumor-associated edema, suggesting their potential as novel therapeutic targets. Despite this, the development of selective and potent AQP inhibitors has proven challenging. Efforts to produce small-molecule AQP inhibitors have largely been unsuccessful. However, recent advancements include monoclonal human IgG antibodies targeting extracellular domains of aquaporin-4, offering new therapeutic strategies, particularly in glioblastoma, where AQP-4 is overexpressed. However, recent advancements include monoclonal human IgG antibodies targeting extracellular domains of aquaporin-4, offering new therapeutic strategies, particularly in glioblastoma, where AQP-4 is over expressed. These antibodies hold promise for selectively targeting and eradicating AQP-4-expressing cells in malignant brain tumors. This review discusses the critical role AQPs play in cancer, including their contributions to tumor cell proliferation, migration, angiogenesis, and edema formation. Additionally, we explore innovative therapeutic approaches, such as antibody-based interventions, and outline potential future research directions in AQP-targeted cancer therapies.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of coumarin-inspired bifunctional hybrids as a new class of anti-Alzheimer's agents with potent in vivo efficacy. 香豆素激发的双功能杂交体的开发作为一类新的抗阿尔茨海默病药物具有强大的体内疗效。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-11 DOI: 10.1039/d4md00782d
Atamjit Singh, Aman Sharma, Karanvir Singh, Kirandeep Kaur, Pallvi Mohana, Jignesh Prajapati, Uttam Kaur, Dweipayan Goswami, Saroj Arora, Renu Chadha, Preet Mohinder Singh Bedi

Considering the multifactorial and complex nature of Alzheimer's disease and the requirement of an optimum multifunctional anti-Alzheimer's agent, a series of triazole tethered coumarin-eugenol hybrid molecules was designed as potential multifunctional anti-Alzheimer's agents using donepezil and a template. The designed hybrid molecules were synthesized via a click chemistry approach and preliminarily screened for cholinesterase and Aβ1-42 aggregation inhibition. Among them, AS15 emerged as a selective inhibitor of AChE (IC50 = 0.047 μM) over butyrylcholinesterase (BuChE: IC50 ≥ 10 μM) with desired Aβ1-42 aggregation inhibition (72.21% at 50 μM) properties. In addition, AS15 showed protective effects against DNA damage caused by hydroxyl radicals originating from H2O2. Molecular docking and simulation studies confirmed the favorable interactions of AChE and the Aβ1-42 monomer desired for their inhibition. AS15 exhibited an LD50 value of 300 mg kg-1 and showed significant improvements in memory and learning behavior in scopolamine-induced cognition impairment mouse-based animal models (Y-maze test and Morris water maze test) for behavioral analysis. Overall outcomes suggest AS15 as a potential preclinical multifunctional candidate for the management of Alzheimer's disease, and it serves as a promising lead for further development of potent and safer multifunctional anti-Alzheimer's agents.

考虑到阿尔茨海默病的多因素和复杂性,以及对最佳多功能抗阿尔茨海默病药物的需求,以多奈哌齐为模板,设计了一系列三唑系香豆素-丁香酚杂化分子作为潜在的多功能抗阿尔茨海默病药物。设计的杂化分子通过点击化学方法合成,并初步筛选了胆碱酯酶和a - β1-42聚集抑制作用。其中,AS15作为乙酰胆碱酯酶(BuChE: IC50≥10 μM)的选择性抑制剂(IC50 = 0.047 μM),具有良好的a - β1-42聚集抑制性能(50 μM时为72.21%)。此外,AS15对H2O2产生的羟基自由基引起的DNA损伤具有保护作用。分子对接和模拟研究证实了乙酰胆碱酯酶与a - β1-42单体的良好相互作用。AS15的LD50值为300 mg kg-1,在东莨菪碱诱导的认知障碍小鼠动物模型(y迷宫实验和Morris水迷宫实验)中表现出显著的记忆和学习行为改善。总体结果表明,AS15是治疗阿尔茨海默病的潜在临床前多功能候选药物,它是进一步开发更有效、更安全的多功能抗阿尔茨海默病药物的有希望的先导。
{"title":"Development of coumarin-inspired bifunctional hybrids as a new class of anti-Alzheimer's agents with potent <i>in vivo</i> efficacy.","authors":"Atamjit Singh, Aman Sharma, Karanvir Singh, Kirandeep Kaur, Pallvi Mohana, Jignesh Prajapati, Uttam Kaur, Dweipayan Goswami, Saroj Arora, Renu Chadha, Preet Mohinder Singh Bedi","doi":"10.1039/d4md00782d","DOIUrl":"10.1039/d4md00782d","url":null,"abstract":"<p><p>Considering the multifactorial and complex nature of Alzheimer's disease and the requirement of an optimum multifunctional anti-Alzheimer's agent, a series of triazole tethered coumarin-eugenol hybrid molecules was designed as potential multifunctional anti-Alzheimer's agents using donepezil and a template. The designed hybrid molecules were synthesized <i>via</i> a click chemistry approach and preliminarily screened for cholinesterase and Aβ<sub>1-42</sub> aggregation inhibition. Among them, AS15 emerged as a selective inhibitor of AChE (IC<sub>50</sub> = 0.047 μM) over butyrylcholinesterase (BuChE: IC<sub>50</sub> ≥ 10 μM) with desired Aβ<sub>1-42</sub> aggregation inhibition (72.21% at 50 μM) properties. In addition, AS15 showed protective effects against DNA damage caused by hydroxyl radicals originating from H<sub>2</sub>O<sub>2</sub>. Molecular docking and simulation studies confirmed the favorable interactions of AChE and the Aβ<sub>1-42</sub> monomer desired for their inhibition. AS15 exhibited an LD<sub>50</sub> value of 300 mg kg<sup>-1</sup> and showed significant improvements in memory and learning behavior in scopolamine-induced cognition impairment mouse-based animal models (Y-maze test and Morris water maze test) for behavioral analysis. Overall outcomes suggest AS15 as a potential preclinical multifunctional candidate for the management of Alzheimer's disease, and it serves as a promising lead for further development of potent and safer multifunctional anti-Alzheimer's agents.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An estrogen receptor β-targeted near-infrared probe for theranostic imaging of prostate cancer.
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-11 DOI: 10.1039/d4md00767k
Junhong Dai, Yihe Wu, Xiaofei Deng, Hai-Bing Zhou, Chune Dong

Estrogen receptor β (ERβ) is aberrantly expressed in castration-resistant prostate cancer (CRPC). Therefore, a diagnostic and therapeutic ERβ probe not only helps to reveal the complex role of ERβ in prostate cancer (PCa), but also promotes ERβ-targeted PCa therapy. Herein, we reported a novel ERβ-targeted near-infrared fluorescent probe D3 with both imaging and therapeutic functions, which had the advantages of high ERβ selectivity, good optical performance, and strong anti-interference ability. In addition, it displayed excellent antiproliferative activity in CRPC cells. Finally, D3 was also successfully applied to the in vivo imaging of ERβ in the prostate cancer mouse model. Thus, this ERβ-targeted near-infrared fluorescent probe can be used as a potential tool for the study of ERβ-targeted diagnostic and therapeutic PCa.

{"title":"An estrogen receptor β-targeted near-infrared probe for theranostic imaging of prostate cancer.","authors":"Junhong Dai, Yihe Wu, Xiaofei Deng, Hai-Bing Zhou, Chune Dong","doi":"10.1039/d4md00767k","DOIUrl":"10.1039/d4md00767k","url":null,"abstract":"<p><p>Estrogen receptor β (ERβ) is aberrantly expressed in castration-resistant prostate cancer (CRPC). Therefore, a diagnostic and therapeutic ERβ probe not only helps to reveal the complex role of ERβ in prostate cancer (PCa), but also promotes ERβ-targeted PCa therapy. Herein, we reported a novel ERβ-targeted near-infrared fluorescent probe D3 with both imaging and therapeutic functions, which had the advantages of high ERβ selectivity, good optical performance, and strong anti-interference ability. In addition, it displayed excellent antiproliferative activity in CRPC cells. Finally, D3 was also successfully applied to the <i>in vivo</i> imaging of ERβ in the prostate cancer mouse model. Thus, this ERβ-targeted near-infrared fluorescent probe can be used as a potential tool for the study of ERβ-targeted diagnostic and therapeutic PCa.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sulphonyl thiourea compounds containing pyrimidine as dual inhibitors of I, II, IX, and XII carbonic anhydrases and cancer cell lines: synthesis, characterization and in silico studies. 含嘧啶的磺基硫脲化合物作为I、II、IX和XII碳酸酐酶和癌细胞系的双重抑制剂:合成、表征和硅研究。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-11 DOI: 10.1039/d4md00816b
Nguyen Dinh Thanh, Vu Ngoc Toan, Vu Minh Trang

Some novel sulphonyl thiourea derivatives (7a-m) containing 4,6-diarylpyrimidine rings were designed and synthesized using a one-pot procedure. These compounds exhibited remarkable dual inhibitory activity against human carbonic anhydrase hCA I, hCA II, hCA IX, and XII isoenzymes and some cancer cell lines. Among them, some thioureas had significantly more potent inhibitory activities in the order of 7l > 7c > 7f (against the hCA I isoform), 7f > 7b > 7c (against the hCA II isoform), 7c > 7g > 7a > 7b (against the hCA IX isoform), and 7d > 7c > 7g > 7f (against the hCA XII isoform). The obtained inhibitory activity data against the hCA IX and XII isoforms showed that compound 7c was the most potent inhibitor in this sulphonyl thiourea series against enzyme hCA IX, with K I = 125.1 ± 12.4 nM, while compound 7d was the most potent inhibitor against enzyme hCA XII, with K I = 111.0 ± 12.3 nM. Compound 7c exhibited strong inhibitory activity among all four tested hCA enzymes, while thiourea 7f was a potent inhibitor for enzymes hCA I, II and XII. All these compounds demonstrated non-competitive inhibition of both enzymes. Some selected potential inhibitory compounds, including 7c, 7d, and 7g, exhibited remarkable cytotoxic activity against human cancer cell lines, including human breast adenocarcinoma (MCF-7), human liver adenocarcinoma (HepG2), human cervical epithelial carcinoma (HeLa), and human lung adenocarcinoma cells (A549). These compounds exhibited low cytotoxicity in the WI-38 cell line. The compounds 7c and 7d were the most potent inhibitors against tumour-associated hCA IX and hCA XII isoenzymes. Furthermore, these compounds exhibited remarkable inhibition against some cancer cell lines, such as MCF-7, HepG2, HeLa, and A549. They were subjected to in silico screening for molecular docking and molecular dynamics simulations. The results of in vitro and in silico studies revealed that compounds 7c and 7d were the most promising derivatives in this series owing to their significant effects on the studied hCA IX and hCA XII isoenzymes, respectively. The results showed that the sulphonyl thiourea moiety was deeply accommodated in the active site and interacted with zinc ions in the receptors.

设计并合成了一些新型的含有4,6-二芳基嘧啶环的磺胺基硫脲衍生物(7a-m)。这些化合物对人碳酸酐酶hCA I、hCA II、hCA IX和hCA XII同工酶和一些癌细胞具有显著的双重抑制活性。其中,部分硫脲对hCA I异构体的抑制活性为71> 7c >7f,对hCA II异构体的抑制活性为71> 7b >c,对hCA IX异构体的抑制活性为71> 7g > 7a > 7b,对hCA XII异构体的抑制活性为71> 7c > 7g > 7f。对hCA IX和hCA XII亚型的抑制活性数据表明,化合物7c对hCA IX酶的抑制作用最强,K I = 125.1±12.4 nM,而化合物7d对hCA XII酶的抑制作用最强,K I = 111.0±12.3 nM。化合物7c对四种hCA酶均有较强的抑制活性,而硫脲7f对hCA I、II和XII酶均有较强的抑制作用。所有这些化合物均表现出对两种酶的非竞争性抑制作用。一些选定的潜在抑制化合物,包括7c, 7d和7g,对人类癌细胞系,包括人乳腺腺癌(MCF-7),人肝腺癌(HepG2),人宫颈上皮癌(HeLa)和人肺腺癌细胞(A549)显示出显著的细胞毒活性。这些化合物在WI-38细胞系中表现出较低的细胞毒性。化合物7c和7d是肿瘤相关hCA IX和hCA XII同工酶的最有效抑制剂。此外,这些化合物对MCF-7、HepG2、HeLa和A549等癌细胞具有显著的抑制作用。他们进行了分子对接和分子动力学模拟的硅筛选。体外和硅内实验结果表明,化合物7c和7d分别对hCA IX和hCA XII同工酶具有显著的影响,是该系列中最有前途的衍生物。结果表明,巯基硫脲部分被深度安置在活性位点,并与受体中的锌离子相互作用。
{"title":"Sulphonyl thiourea compounds containing pyrimidine as dual inhibitors of I, II, IX, and XII carbonic anhydrases and cancer cell lines: synthesis, characterization and <i>in silico</i> studies.","authors":"Nguyen Dinh Thanh, Vu Ngoc Toan, Vu Minh Trang","doi":"10.1039/d4md00816b","DOIUrl":"10.1039/d4md00816b","url":null,"abstract":"<p><p>Some novel sulphonyl thiourea derivatives (7a-m) containing 4,6-diarylpyrimidine rings were designed and synthesized using a one-pot procedure. These compounds exhibited remarkable dual inhibitory activity against human carbonic anhydrase <i>h</i>CA I, <i>h</i>CA II, <i>h</i>CA IX, and XII isoenzymes and some cancer cell lines. Among them, some thioureas had significantly more potent inhibitory activities in the order of 7l > 7c > 7f (against the <i>h</i>CA I isoform), 7f > 7b > 7c (against the <i>h</i>CA II isoform), 7c > 7g > 7a > 7b (against the <i>h</i>CA IX isoform), and 7d > 7c > 7g > 7f (against the <i>h</i>CA XII isoform). The obtained inhibitory activity data against the <i>h</i>CA IX and XII isoforms showed that compound 7c was the most potent inhibitor in this sulphonyl thiourea series against enzyme <i>h</i>CA IX, with <i>K</i> <sub>I</sub> = 125.1 ± 12.4 nM, while compound 7d was the most potent inhibitor against enzyme <i>h</i>CA XII, with <i>K</i> <sub>I</sub> = 111.0 ± 12.3 nM. Compound 7c exhibited strong inhibitory activity among all four tested <i>h</i>CA enzymes, while thiourea 7f was a potent inhibitor for enzymes <i>h</i>CA I, II and XII. All these compounds demonstrated non-competitive inhibition of both enzymes. Some selected potential inhibitory compounds, including 7c, 7d, and 7g, exhibited remarkable cytotoxic activity against human cancer cell lines, including human breast adenocarcinoma (MCF-7), human liver adenocarcinoma (HepG2), human cervical epithelial carcinoma (HeLa), and human lung adenocarcinoma cells (A549). These compounds exhibited low cytotoxicity in the WI-38 cell line. The compounds 7c and 7d were the most potent inhibitors against tumour-associated <i>h</i>CA IX and <i>h</i>CA XII isoenzymes. Furthermore, these compounds exhibited remarkable inhibition against some cancer cell lines, such as MCF-7, HepG2, HeLa, and A549. They were subjected to <i>in silico</i> screening for molecular docking and molecular dynamics simulations. The results of <i>in vitro</i> and <i>in silico</i> studies revealed that compounds 7c and 7d were the most promising derivatives in this series owing to their significant effects on the studied <i>h</i>CA IX and <i>h</i>CA XII isoenzymes, respectively. The results showed that the sulphonyl thiourea moiety was deeply accommodated in the active site and interacted with zinc ions in the receptors.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study. 探测非肽激动剂与人类痛觉肽/孤啡肽FQ受体的结合:分子模型研究。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-10 DOI: 10.1039/d4md00747f
Matteo Gozzi, Davide Malfacini, Valentina Albanese, Salvatore Pacifico, Delia Preti, Remo Guerrini, Girolamo Calò, Antonella Ciancetta

The N/OFQ-NOP receptor is a fascinating peptidergic system with the potential to be exploited for the development of analgesic drugs devoid of side effects associated with classical opioid signalling modulation. To date, up to four X-ray and cryo-EM structures of the NOP receptor in complex with the endogenous peptide agonist N/OFQ and three small molecule antagonists have been solved and released. Despite the available structural information, the details of selective small molecule agonist binding to the NOP receptor in the active state remain elusive. In this study, by leveraging the available structural information and using N/OFQ(1-13)-NH2 as a reference compound, we developed a computational protocol based on docking followed by short molecular dynamics (MD) simulations that can suggest small molecule agonist binding modes at the NOP receptor that are reproducible and stable over time in the solvated membrane-embedded receptor active state and in agreement with known structure-activity relationship (SAR) data.

N/OFQ-NOP受体是一个令人着迷的肽能系统,有潜力用于开发无副作用的镇痛药物,与经典的阿片信号调节相关。迄今为止,NOP受体与内源性肽激动剂N/OFQ和三种小分子拮抗剂复合物的x射线和低温电镜结构已被破解和释放。尽管有可用的结构信息,但选择性小分子激动剂在活性状态下与NOP受体结合的细节仍然难以捉摸。在这项研究中,利用现有的结构信息,并以N/OFQ(1-13)-NH2作为参考化合物,我们开发了一种基于对接和短分子动力学(MD)模拟的计算方案,该方案可以建议小分子激动剂在NOP受体上的结合模式,该模式在溶剂化膜嵌入受体活性状态下可重复且稳定,并且与已知的结构-活性关系(SAR)数据一致。
{"title":"Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study.","authors":"Matteo Gozzi, Davide Malfacini, Valentina Albanese, Salvatore Pacifico, Delia Preti, Remo Guerrini, Girolamo Calò, Antonella Ciancetta","doi":"10.1039/d4md00747f","DOIUrl":"10.1039/d4md00747f","url":null,"abstract":"<p><p>The N/OFQ-NOP receptor is a fascinating peptidergic system with the potential to be exploited for the development of analgesic drugs devoid of side effects associated with classical opioid signalling modulation. To date, up to four X-ray and cryo-EM structures of the NOP receptor in complex with the endogenous peptide agonist N/OFQ and three small molecule antagonists have been solved and released. Despite the available structural information, the details of selective small molecule agonist binding to the NOP receptor in the active state remain elusive. In this study, by leveraging the available structural information and using N/OFQ(1-13)-NH<sub>2</sub> as a reference compound, we developed a computational protocol based on docking followed by short molecular dynamics (MD) simulations that can suggest small molecule agonist binding modes at the NOP receptor that are reproducible and stable over time in the solvated membrane-embedded receptor active state and in agreement with known structure-activity relationship (SAR) data.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploiting the DCAF16-SPIN4 interaction to identify DCAF16 ligands for PROTAC development. 利用DCAF16- spin4相互作用鉴定用于PROTAC开发的DCAF16配体。
IF 4.1 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-06 DOI: 10.1039/d4md00681j
Isabella A Riha, Miguel A Campos, Xiaokang Jin, Fiona Y Wang, Chenlu Zhang, Sara F Dunne, Benjamin F Cravatt, Xiaoyu Zhang

Traditional small molecule drugs often target protein activity directly, but challenges arise when proteins lack suitable functional sites. An alternative approach is targeted protein degradation (TPD), which directs proteins to cellular machinery for proteolytic degradation. Recent studies have identified additional E3 ligases suitable for TPD, expanding the potential of this approach. Among these, DCAF16 has shown promise in facilitating protein degradation through both PROTAC and molecular glue mechanisms. In this study, we developed a homogeneous time resolved fluorescence (HTRF) assay to discover new DCAF16 binders. Using an in-house electrophile library, we identified two diastereomeric compounds, with one engaging DCAF16 at cysteines C177-179 and another reducing its expression. We demonstrated that the compound covalently engaging DCAF16 can be transformed into a PROTAC capable of degrading FKBP12.

传统的小分子药物通常直接针对蛋白质的活性,但当蛋白质缺乏合适的功能位点时,就会出现挑战。另一种方法是靶向蛋白质降解(TPD),它将蛋白质引导到细胞机制中进行蛋白水解降解。最近的研究发现了更多适合 TPD 的 E3 连接酶,扩大了这种方法的潜力。其中,DCAF16 已显示出通过 PROTAC 和分子胶机制促进蛋白质降解的前景。在这项研究中,我们开发了一种均相时间分辨荧光(HTRF)测定法来发现新的 DCAF16 结合体。利用内部亲电子库,我们发现了两种非对映化合物,其中一种能与半胱氨酸 C177-179 上的 DCAF16 结合,另一种则能降低其表达。我们证明,共价结合 DCAF16 的化合物可以转化为能够降解 FKBP12 的 PROTAC。
{"title":"Exploiting the DCAF16-SPIN4 interaction to identify DCAF16 ligands for PROTAC development.","authors":"Isabella A Riha, Miguel A Campos, Xiaokang Jin, Fiona Y Wang, Chenlu Zhang, Sara F Dunne, Benjamin F Cravatt, Xiaoyu Zhang","doi":"10.1039/d4md00681j","DOIUrl":"10.1039/d4md00681j","url":null,"abstract":"<p><p>Traditional small molecule drugs often target protein activity directly, but challenges arise when proteins lack suitable functional sites. An alternative approach is targeted protein degradation (TPD), which directs proteins to cellular machinery for proteolytic degradation. Recent studies have identified additional E3 ligases suitable for TPD, expanding the potential of this approach. Among these, DCAF16 has shown promise in facilitating protein degradation through both PROTAC and molecular glue mechanisms. In this study, we developed a homogeneous time resolved fluorescence (HTRF) assay to discover new DCAF16 binders. Using an in-house electrophile library, we identified two diastereomeric compounds, with one engaging DCAF16 at cysteines C177-179 and another reducing its expression. We demonstrated that the compound covalently engaging DCAF16 can be transformed into a PROTAC capable of degrading FKBP12.</p>","PeriodicalId":21462,"journal":{"name":"RSC medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11647575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
RSC medicinal chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1